BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Core Viewpoint - A securities fraud lawsuit has been filed against Capricor Therapeutics, Inc. and certain executives, alleging false statements regarding the safety and efficacy of their drug candidate, deramiocel, leading to significant investor losses [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Capricor Therapeutics misled investors about deramiocel's progress towards FDA approval while concealing adverse data from the Phase 2 HOPE-2 trial [2]. - Following the release of negative information, Capricor's stock price experienced significant declines: from $10.30 to $7.30 on May 5, 2025; from $11.94 to $8.26 on June 20, 2025; and from $11.40 to $7.64 after the FDA's Complete Response Letter on July 11, 2025 [2]. Group 2: Eligibility and Actions - Investors who purchased Capricor common stock between October 9, 2024, and July 10, 2025, and have incurred losses may be eligible to participate in the lawsuit [3]. - The deadline to seek appointment as lead plaintiff is September 15, 2025, and investors are encouraged to contact Block & Leviton for further information [4]. Group 3: Whistleblower Information - Individuals with non-public information about Capricor Therapeutics are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 4: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].